Summary
Updated Aug 30, 2026
Alfred J. Novak is Director of Pasithea Therapeutics Corp. (KTTA). 2 SEC Form 4 filings on record going back to 2025, most recently on 5 May 2026.
Trading Pattern
InsiderAlpha's records for Alfred J. Novak go back to 2025: 2 primary Form 4 filings, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Alfred J. Novak files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Lawrence Steinman - $100K of KTTA open-market activity in the last 12 months
- Coastlands Capital LP - $53K of KTTA open-market activity in the last 12 months
- Tiago Marques - $25K of KTTA open-market activity in the last 12 months
- Simon Dumesnil - $25K of KTTA open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Alfred J. Novak?
Alfred J. Novak is a corporate insider, tracked as Director of Pasithea Therapeutics Corp. (KTTA). InsiderAlpha holds 2 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Alfred J. Novak last file a Form 4?
The most recent primary Form 4 on record is dated 5 May 2026, one of 2 filings going back to 2025.
Where can I see all of Alfred J. Novak's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Alfred J. Novak and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial